Loading…
Bafna Pharmaceuticals (BAFNAPH)₹472.80+2.00%Pharmaceuticals
Bafna Pharmaceuticals is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 100.0 against a peer median of 42.1, and ROCE of 11.9% against a peer median of 10.9%, and latest-quarter sales growth of 8.1% against a peer median of 13.9%. By market cap it is #6 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Anlon Healthcare | 1,433 | 42.1 | 21.0 | 18.4 | 0.19 | 0.0 | 173 | 29 | 103.7 | 89.0 | vs BAFNAPH |
| Bharat Parenterals | 1,308 | 1,047.0 | −2.0 | −2.6 | 0.45 | 0.1 | 344 | −27 | 109.3 | — | vs BAFNAPH |
| Fermenta Biotech | 1,267 | 21.2 | 21.0 | 16.4 | 0.28 | 0.9 | 524 | 70 | −10.7 | −55.8 | vs BAFNAPH |
| Kopran | 1,252 | 50.0 | 7.0 | 4.9 | 0.29 | 1.2 | 683 | 26 | 13.9 | −10.0 | vs BAFNAPH |
| Bharat Parenterals | 1,243 | 994.9 | −2.0 | −2.6 | 0.45 | 0.1 | 345 | −27 | 109.1 | — | vs BAFNAPH |
| Bafna Pharmaceuticals | 1,121 | 100.0 | 11.9 | 12.4 | 0.39 | 0.0 | 150 | 11 | 8.1 | 109.1 | — |
| Bajaj Healthcare | 1,062 | 54.5 | 10.9 | 9.4 | 0.47 | 0.5 | 608 | 16 | 11.5 | 16.5 | vs BAFNAPH |
| Lincoln Pharmaceuticals | 1,043 | 10.8 | 16.0 | 12.0 | 0.01 | 0.3 | 672 | 88 | 17.3 | 0.0 | vs BAFNAPH |
| Sigachi Industries | 1,036 | 38.2 | 6.0 | 5.8 | 0.27 | 0.4 | 478 | −83 | −5.4 | — | vs BAFNAPH |
| Remus Pharmaceuticals | 968 | 26.2 | 17.1 | 12.3 | 0.08 | 0.1 | 853 | 46 | 30.2 | 19.1 | vs BAFNAPH |
| Themis Medicare | 939 | 23.5 | 3.0 | 0.4 | 0.25 | 0.5 | 342 | 1 | −11.1 | — | vs BAFNAPH |
| Peer median | 1,121 | 42.1 | 10.9 | 9.4 | 0.28 | 0.3 | 478 | 16 | 13.9 | 16.5 |
Listed companies closest to Bafna Pharmaceuticals in Pharmaceuticals include Anlon Healthcare, Bharat Parenterals, Fermenta Biotech, Kopran, Bharat Parenterals, Bajaj Healthcare, Lincoln Pharmaceuticals, Sigachi Industries.
Anlon Healthcare, with a market cap of ₹1,433 Cr.
Bafna Pharmaceuticals trades at a P/E of 100.0; the median of its peer set is 42.1. A P/E above or below the median is a description, not a judgement on value.
Bafna Pharmaceuticals' return on capital employed is 11.9%, above the peer median of 10.9%.